UC-USP collaborative exercise on photobiomodulation therapy in neurological orofacial disturbances by Nunes, Tiago et al.
J Clin Exp Dent. 2020;12(7):e644-9.                                                                                                                                                                                  PBMT in neurological orofacial disturbances
e650
Journal section: Oral Medicine and Pathology                      
Publication Types: Research
UC-USP collaborative exercise on photobiomodulation 
therapy in neurological orofacial disturbances 
Tiago Nunes 1, Catarina Caetano 1,2, Miguel Pimenta 1, José Saraiva 1, Salomão Rocha 1, Patrícia Freitas 3, José 
Figueiredo 1, Sónia-Alves Pereira 1, Ana Corte-Real 1,2
1 Faculty of Medicine, University of Coimbra, Coimbra, Portugal
2 Forensic Dentistry Laboratory, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
3 Special Laboratory of Lasers in Dentistry, School of Dentistry, University of São Paulo, São Paulo, Brazil
Correspondence:
Faculdade de Medicina da Universidade de Coimbra
Pólo III
Azinhaga de Santa Comba





Background: Neurosensory peripheral disorders are one of the most common risks associated with iatrogenic and/
or post-traumatic injuries. It is often related to disability. Photobiomodulation therapy (PBMT) is a nonsurgical 
and safe procedure which can accelerate and improve the regeneration of injured biological tissue. This study aims 
to analyze the impact of PBMT, in the quality of life and impairment of individuals with orofacial neurological 
peripheral disturbance. 
Material and Methods: A retrospective analysis in the database of the dental traumatology clinic of the Hospital 
Centre of the University of Coimbra/Faculty of Medicine of the University of Coimbra was performed.5 out of 50 
individuals were selected, according to the selection criteria. The neurosensory activity was assessed by a pinprick 
nociceptive test and the EQ-5D-5L self-report questionnaire was used to analyse the quality of life. The study was 
performed in two phases:1) inactive laser or placebo phase, for one month and 2) active laser or treatment phase. A 
diode low-level laser device (SIROLaserBlue;Sirona,Germany) was used, according to our protocol. A collaborati-
ve protocol in the PBMT influence in individuals with neurosensory peripheral disturbances was studied.
Results: There was no improvement in the neurosensory activity nor in the quality of life, in the placebo phase. 
After the treatment phase, the EQ-5D-5L final results reported no problems in all of the five dimensions, except for 
anxiety/depression in individuals with long-standing neurosensory peripheral disturbances. The EQ-VAS scores 
increased in all the individuals.
Conclusions: Our results supported the improvement of quality of life and impairment reduction in the individuals 
submitted to PBMT.
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Introduction
In the maxillofacial region, nerve injuries may occur as 
a result of trauma, neoplasms, infections and secondary 
to oral and/or maxillofacial surgical procedures (1), such 
as dental implant placement, orthognathic surgery, too-
th extractions and surgical treatment of fractures (1-3). 
Nonsurgical procedures, including endodontic treatment 
and local anesthetics administration, can also cause ner-
ve injuries (1,3).
Although many classifications for nerve injuries have 
been proposed, the two most widely used are those 
developed by Seddon and Sunderland (1,2,4). Seddon 
classifies the injuries by severity, with anatomic criteria, 
as neuropraxia, axonotmesis and neurotmesis (1,4), Sun-
derland focuses on the fascicular structure of the nerve 
and the remaining integrity following injury (1,4).
Nerve injuries are commonly associated with sensory 
disorders (5). Recently, the Association for the Study 
of Pain has categorized the most frequently used des-
criptive terms of neurosensory disorders as anesthesia, 
paresthesia or dysesthesia, each one with relative subca-
tegories (6). Anesthesia refers to the total loss of feeling 
or sensation (6,7). Paresthesia is limited to an abnormal 
sensation that is not unpleasant (6,7). Dysesthesia repre-
sents any abnormal sensation that is unpleasant (6,7).
Although neurosensory recovery may be spontaneous, 
some injuries may be considered permanent, with seque-
lae ranging from a nonpainful minor loss of sensation 
and/or function to a major dysfunction (6,8). Neurosen-
sory peripheral disorders often interfere with the indivi-
dual’s ability to perform daily-life activities, eat comfor-
tably, communicate clearly or manage oral secretions, 
resulting in disability (3,4,9).
In order to improve neurosensory recovery, surgical 
and acupuncture treatment alternatives may be availa-
ble with variable outcomes and no consensus about the 
ideal approach (9).
Photobiomodulation therapy (PBMT) is a nonsurgical 
and safe procedure which can accelerate and improve the 
regeneration of injured biological tissue (10-13). PBMT 
is suggested to have an important role in inflammation, 
healing and neurological disturbances (14). PBMT con-
sists on the application of a light that once absorbed 
promotes a photochemical biological effect exerting a 
chemical change (15). To produce any effect on a living 
biological system, the light must be absorbed by electro-
nic bands belonging to some molecular photoacceptors, 
or chromophores, which can be seen in hemoglobin, fla-
voproteins, cytochrome c oxidase and myoglobin (15). 
The initial effects of light are thought to take place in 
the mitochondria and lead to biochemical and cellular 
changes such as increased cell proliferation and migra-
tion (particularly by fibroblasts), modulation in levels of 
cytokines, growth factors and inflammatory mediators 
and increased tissue oxygenation (14,16). This techni-
que is referred to as Low-Level since the optimum dose 
of light delivered is low and not comparable to other 
forms of laser procedures used for cutting, ablation and 
thermal tissue coagulation (14,16). Lower or higher 
doses than the optimum value will have respectively, a 
minor therapeutic outcome or even a negative outcome 
(14,16).
This study is carried in cooperation with the Special 
Laboratory of Lasers in Dentistry, School of Dentistry 
- University of São Paulo, as a collaborative exercise. It 
aims to analyze the impact Low-Level Laser Therapy, in 
the quality of life and impairment, of individuals with 




A retrospective analysis in the database of the dental 
traumatology clinic of the Hospital Centre of the Univer-
sity of Coimbra / Faculty of Medicine of the University 
of Coimbra was performed. The individuals were selec-
ted, by the research team, according to the inclusion and 
exclusion criteria. Inclusion criteria were: age between 
18 and 65 years; evaluation of orofacial civil damage; 
traumatic or iatrogenic etiology; orofacial impairment 
value, with medico-legal evaluation, secondary to func-
tional and sensitive sequelae of the neurological system 
at March 2019. Exclusion criteria were the presence of: 
neurosensory disturbances before the procedures, con-
comitant therapy or medication, oncological diseases 
and incompatible area of residence. 
-Clinical Evaluation of Peripheral Nerve Injury, Quality 
of Life and Impairment Assessment.
The research team carefully informed the individuals 
about the objectives of the study and asked them to agree 
to participate by signing an informed consent. 
It was performed a self-report questionnaire, conside-
ring: the area affected, the assumption of traumatic or 
technical procedure cause, the chronological evolution 
and characterization of the symptoms, the consequences 
of the injury in the social, professional and daily life. 
Each patient was asked to complete a quality of life ques-
tionnaire, EQ-5D-5L, before and after the treatment. 
The questionnaire consists of two parts: the EQ-5D-5L 
descriptive system and the EQ Visual Analogue scale 
(EQ-VAS). The descriptive system contains five dimen-
sions (mobility, self-care, usual activities, pain/discom-
fort, anxiety/depression). Each dimension has 5 levels 
of severity (1-no problems; 2-slight problems; 3-mode-
rate problems; 4-severe problems; 5-extreme problems). 
The respondent is asked to indicate his/her health state 
by ticking the box matching the most appropriate state-
ment in each of the 5 dimensions. The EQ VAS records 
the respondent’s self-rated health on a visual analogue 
scale with endpoints labelled “the best health you can 
imagine” and “the worst health you can imagine.” (17). 
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The English version of the questionnaire was used and 
a member of the research team would clarify any aspect 
the individuals would not comprehend.   
-Objective examination 
The research team, three dental doctors with forensic/or-
thodontic/prosthodontic practice and one pre graduated stu-
dent, proceeded with the individual/objective examination.
The neurosensory peripheral disturbance was assessed 
by a pinprick nociceptive test using a 30-gauge disposa-
ble needle to determine the patient’s sensibility response 
at the beginning of each treatment session. The patient 
was positioned comfortably with eyes closed, while one 
trained professional applied pressure with the tip of the 
needle and recorded the patient’s perception according 
to the response in a contralateral or nearest unaffected 
point as: (-) Total loss of sensation; (+) Partial loss of 
sensation; (#) Normal sensation (equal to control). Per-
ception record and mapping were done by taking notes 
on a standardized drawing on a printed examination 
form. Additionally, a dermatograph pencil was used for 
mapping the affected area on the patient’s face and pho-
tographs were taken.
-PBMT Protocol
To address the research purpose, the study was perfor-
med in two phases: 1) inactive laser or placebo phase, 
for one month; 2) active laser or treatment phase and a 
follow-up visit.
A diode low-level laser device (SIROLaser Blue; Siro-
na, Bensheim, Germany) was used to irradiate the whole 
area enervated by the affected nerve twice a week. The 
laser device was set to deliver 100mW continuous wave 
at 660nm. The irradiation was performed in contact 
with the skin or mucosa using a light guide (MultiTip 
8mm) perpendicular to the area to be treated for 40s per 
point, 4J per point, with a distance of 1cm between each 
irradiation point. If extra-oral irradiation was required, 
asepsis was performed on the patient’s skin with a 70% 
alcohol swab, to prevent harmful interference with subs-
tances in the absorption of the laser light. 
In the first phase, placebo laser, the same protocol was 
used but the laser was inactive. This phase lasted 4 
weeks, for a total of 8 sessions. In the active laser or 
treatment phase, the number of treatment sessions was 
determined by the patient’s clinical improvement, until 
total recovery was achieved. 1 month after the treatment 
phase was completed, a follow-up visit was scheduled.
Results
A total of 50 individuals were enrolled in this study. 46 
individuals were excluded for not meeting the inclu-
sion criteria, ultimately providing 5 individuals for data 
analysis. During the treatment phase 1), 1 patient wi-
thdrawn from the study for personal reasons. The flow 
diagram of patient selection is shown in Figure 1.
All the included subjects were female with a mean age 
of 41 years old. The frequency of patient-reported dai-
ly-life activities in the initial examination is presented in 
table 1. After the PBMT, treatment phase 2) was com-
pleted no disabilities were reported, (Tables 2,3).
There was no change in the neurosensory recovery nor 
in the self-reported quality of life at the end of treatment 
phase 1), placebo laser.
Fig. 1: Flow diagram of patient selection.
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Daily-life activities Nº of 
individuals
Masticatory Involuntary cheek biting 4
Burning of the lip or tongue with hot fluids/food 1
Dribbling of food or drooling of liquids/saliva 3
Difficulty chewing food 3
Difficulty swallowing 3
Decreased or altered taste sensation 1
Esthetic Difficulty speaking 2
Difficulty smiling/laughing 3
Difficulty sleeping 3
Difficulty with toothbrushing 3
Difficulty applying makeup 2
Difficulty performing work duties 3
Interference with relationship with spouse or other 1
Table 1: Frequency of patient-reported disabilities.
Table 2: Demographic and neurosensory peripheral disturbance characteristics and EQ-VAS results.
 
 
N Sex Age Etiology Impairment Value Chronological 
Evolution 
Nº Sessions EQ-VAS 
Baseline Final 
Baseline Final 
1 F 40 IAT 7 0 10 Years 4 40 90 
2 F 41 IAT 7 0 7 Months 4 45 90 
3 F 24 IAT 7 0 1 Month 12 55 90 
4 F 55 TRA 10 PW 4 Years PW 20 PW 
5 F 45 IAT 6 0 6 Months 4 60 98 
 Legend: IAT- Iatrogenic; TRA- Traumatic; PW- Patient Withdrawal.
N EQ-5D-5L
Mobility Selfcare Usual Activities Pain/ Discomfort Anxiety/ Depression
Baseline Final Baseline Final Baseline Final Baseline Final Baseline Final
1 1 1 2 1 1 1 3 1 3 2
2 1 1 2 1 1 1 2 1 3 2
3 1 1 2 1 2 1 4 1 3 1
4 4 PW 4 PW 4 PW 3 PW 4 PW
5 1 1 3 1 3 1 4 1 4 1
Table 3: EQ-5D-5L descriptive system baseline and final reported levels of severity.
Legend: 1-no problems; 2-slight problems; 3-moderate problems; 4-severe problems; 5-extreme problems; 
PW- Patient Withdrawal
Discussion
A collaborative protocol in the PBMT influence in indi-
viduals with neurosensory peripheral disturbances was 
studied.  A first evaluation was made based on the qua-
lity of life; a second evaluation was made based on the 
medico/legal evaluation of damage (impairment value). 
The first randomized controlled clinical trial with PBMT 
on neurosensory deficits was reported in 1996. Until 
2018, only 7 were disclosed (10,12,13,18-21). Accor-
ding to Chung et al. (22), PBMT dosimetry is highly 
complicated. Due to the large number of interrelated 
parameters (wavelength, irradiance, pulse structure, 
amongst others), there has not yet been a comprehensive 
study reporting and examining the effect of individually 
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varying all those parameters, and it is unlikely there will 
ever be (22). The World Association for Laser Therapy 
(WALT) dosage guidelines for PBMT do not provide 
dose recommendations for neurosensory peripheral dis-
turbances. The choice of parameters is often depended 
on the practitioner’s personal preference or experience 
rather than on a consensus statement by an authoritative 
body (22). None of the 7 studies (10,12,13,18-21) used a 
standardized protocol.
In this study, the laser device was set to deliver 100mW 
continuous wave at a wavelength of 660nm. The irradia-
tion was performed in contact with the skin or mucosa 
using a light guide (MultiTip 8mm) perpendicular to the 
area to be treated for 40s an 4J per point, 1cm between 
each irradiation point.
The use of PBMT in animals and patients almost exclu-
sively utilizes red and near-infrared light (600-1100nm) 
(15,16). Gigo-Benato et al. (23) demonstrated 660nm 
PBMT with low (10J/cm2) or moderate (60J/cm2) energy 
densities is able to accelerate neuromuscular recovery 
after nerve crush injury in rats.
The treatment sessions were performed twice a week so 
a cumulative effect of PBMT could be achieved. PBMT 
generally requires at least two treatment sessions a week 
for several weeks to achieve clinical significance, with the 
exception of some early treatment of acute injuries (22). A 
retrospective study of 125 clinical cases reported positive 
results in individuals given treatment twice a week (11).
Since each irradiated point will cover about 1-2cm3 of 
tissue, the whole area enervated by the injured nerve was 
irradiated with a distance of 1cm between each irradia-
tion point to assure that a sufficient number of points 
are selected to cover the entire injury. The light guide, 
MultiTip 8mm, was used to cover a wider area on each 
irradiation point and it was used in contact with the tis-
sue surface to reduce light reflection and improve light 
absorption.
The comparison between the studies’ results was ham-
pered by the methodological non-standardization, expli-
citly in the clinical neurosensory disturbance evaluation. 
All of the studies (10,12,13,18-21) included objective 
testing, however with different methodologies. Only 
two studies (12,21) included a subjective assessment, 
which was a self-completed VAS scale in both cases. 
Our evaluation includes both an objective and subjecti-
ve assessment. The objective assessment consisted in a 
pinprick nociceptive test, to determine the extent of the 
nerve injury and to monitor the neurosensory evolution. 
This method allows a simple measurement of response 
to static light touch and painful stimuli (24) and is also 
likely to detect a persistent sensory abnormality (25). 
Unlike any other study, the subjective assessment in our 
study focused on the quality of life evaluation. 
To prepare the quality of life evaluation, an initial exami-
nation and questioning about the neurosensory periphe-
ral disturbance, based on an article by Meyer et al. (24), 
was performed. Its purpose was to determine whether a 
sensory disturbance existed, what caused it, the orofacial 
functional impairment on the patient’s daily life and to 
ascertain whether PBMT was indicated. The EQ-5D-5L 
quality of life questionnaire, which also includes a VAS 
scale, is a standardized measure of health status, appli-
cable to a wide range of injury conditions and treatments 
(17). It provides a simple descriptive profile that can be 
used in the clinical and health-economics evaluation of 
healthcare as well as in population health surveys (17). 
It was used in this study to record the individuals’ health 
profile and self-rated health status and to evaluate the in-
dividuals’ quality of life recovery. The EQ-5D-5L (scale 
with 5 levels of answer) was used instead of the EQ-5D-
3L (scale with 3 levels of answer), since it could signifi-
cantly increase reliability and sensitivity (discriminatory 
power) while maintaining feasibility and potentially re-
ducing ceiling effects.
Our results support the improvement of quality of life 
(baseline mean value= 50; final mean value= 92). The 
results from the quality of life questionnaire showed a 
clear improvement both in the EQ-5D-5L descriptive 
system and the EQ-VAS. In the EQ-5D-5L descriptive 
system the final severity scores reported no problems in 
all of the five dimensions, with the exception of Anxiety/
Depression in individuals with long-standing neurosen-
sory peripheral disturbances. In those cases, there was 
still an improvement in the Anxiety/Depression dimen-
sion to slight level of problem, potentially a post-trau-
matic psychological sequela, which can pose as a bias of 
the study. The self-perceived health score, from the EQ-
VAS, improved in all the individuals. In the long-stan-
ding cases, baseline scores were minor and the varian-
ces between the baseline and final scores were major, 
although the final scores were similar in all the cases.
Our results support the impairment reduction of all in-
dividuals submitted to Low-Level Laser Therapy. This 
item was never evaluated in any past study. The normal 
evolution of a neurological injury ends in its total reco-
very, that is, the cure. When this does not happen, the 
lesion becomes a sequela and may be associated with 
anatomical and/or functional, as well as psycho-social 
disability. In the context of orofacial neurological se-
quelae, its medico-legal/forensic valuation (impairment 
value) corresponds to the affectation of masticatory ac-
tivity, speech and phonation. The professional technical/
medical performance may allow the improvement of the 
clinical scenario and will tend to promote the improve-
ment of the bio-psycho-functional capability of the in-
dividual.
Limitations of our study include small sample size, 
shortness of follow-up and patient dependent test res-
ponses. The difficulty of achieving a sample with the 
same clinical status poses a study bias.
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Conclusions
The results of the present study support a beneficial 
effect of Low-Level Laser Therapy on the improvement 
of quality of life as well as impairment reduction in in-
dividuals with traumatic and/or iatrogenic orofacial pe-
ripheral nerve injuries. 
While the quality of life questionnaire evaluated the pa-
tient’s response, the medico-legal valuation provided an 
unbiased medical evaluation. The use of both approa-
ches resulted in a complementary methodological rela-
tionship.
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